Ablynx has licensed its nanobody platform to Novo Nordisk which hopes to discover and develop single-domain antibody fragment drug candidates.
Reprocell has entered the CRO space through the acquisition of preclinical discovery services Biopta.
The EMA has given the thumbs up to Benepali, a biosimilar of Amgen’s Enbrel developed by Samsung Bioepis, a JV between Biogen and Samsung Biologics.
Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm’s intentions to dominate the bio-conjugation space.
Scientists trying to curb malaria deaths usually concentrate on preventing mosquito bites or developing human vaccines and therapies, but novel gene-editing tool CRISPR is opening up another path.
Brazilian company Eurofarma claims it has developed Latin America’s first home-grown biosimilar.
Abcam has acquired monoclonal antibody production specialist AxioMx in a deal worth up to $45m (€42m).